DK1114028T3 - Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion - Google Patents

Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion

Info

Publication number
DK1114028T3
DK1114028T3 DK99943058T DK99943058T DK1114028T3 DK 1114028 T3 DK1114028 T3 DK 1114028T3 DK 99943058 T DK99943058 T DK 99943058T DK 99943058 T DK99943058 T DK 99943058T DK 1114028 T3 DK1114028 T3 DK 1114028T3
Authority
DK
Denmark
Prior art keywords
ny4y5
linkage
alkyl
cell adhesion
modulate cell
Prior art date
Application number
DK99943058T
Other languages
English (en)
Inventor
Jean-Dominique Bourzat
Alain Commercon
Bruno Jacques Christop Filoche
Neil Victor Harris
Clive Mccarthy
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818641.4A external-priority patent/GB9818641D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DK1114028T3 publication Critical patent/DK1114028T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Secondary Cells (AREA)
DK99943058T 1998-08-26 1999-08-26 Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion DK1114028T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818641.4A GB9818641D0 (en) 1998-08-26 1998-08-26 Chemical compounds
US11000898P 1998-11-25 1998-11-25
PCT/GB1999/002819 WO2000015612A1 (en) 1998-08-26 1999-08-26 Aza-bicycles which modulate the inhibition of cell adhesion

Publications (1)

Publication Number Publication Date
DK1114028T3 true DK1114028T3 (da) 2007-04-30

Family

ID=26314269

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943058T DK1114028T3 (da) 1998-08-26 1999-08-26 Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion

Country Status (21)

Country Link
US (1) US6608084B1 (da)
EP (1) EP1114028B1 (da)
KR (1) KR20010085630A (da)
CN (1) CN1323295A (da)
AT (1) ATE346841T1 (da)
AU (1) AU754557B2 (da)
BR (1) BR9913222A (da)
CA (1) CA2341677A1 (da)
DE (1) DE69934238T2 (da)
DK (1) DK1114028T3 (da)
ES (1) ES2276530T3 (da)
HU (1) HUP0104766A3 (da)
IL (2) IL141596A0 (da)
MX (1) MXPA01001995A (da)
NO (1) NO20010942L (da)
NZ (1) NZ509781A (da)
PL (1) PL346248A1 (da)
PT (1) PT1114028E (da)
SK (1) SK2612001A3 (da)
TR (1) TR200100588T2 (da)
WO (1) WO2000015612A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263162T1 (de) * 1999-05-05 2004-04-15 Aventis Pharma Ltd Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001235806A1 (en) * 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
EP1330432A2 (en) 2000-11-04 2003-07-30 Aventis Pharma Limited Substituted alkanoic acids
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP4583751B2 (ja) * 2001-06-06 2010-11-17 アベンティス・フアーマ・リミテッド 炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
WO2003011815A1 (en) * 2001-07-26 2003-02-13 Celltech R & D Limited Bicyclic heteroaromatic alanines
US7638630B2 (en) * 2002-04-30 2009-12-29 Ucb Pharma S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
JP3910627B2 (ja) 2003-03-12 2007-04-25 ファイザー・プロダクツ・インク ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体
EP1650205B1 (en) 2003-07-24 2012-04-25 Daiichi Sankyo Company, Limited Cyclohexanecarboxylic acid compound
AU2006254772B2 (en) 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) * 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP1957476A1 (en) * 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
US20110166156A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
US20110166194A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Asenapine Prodrugs
WO2011084848A2 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs of heteraromatic compounds
WO2011084846A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8894846B2 (en) * 2010-12-23 2014-11-25 Stephen Lee Yarbro Using supercritical fluids to refine hydrocarbons
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1497118A1 (de) * 1965-05-29 1969-04-17 Agfa Gevaert Ag Sensibilisierte elektrophotographische Schichten
EP0042298B1 (en) * 1980-06-18 1984-09-12 May & Baker Limited Indole and indoline derivatives
DE68920147T2 (de) * 1989-10-12 1995-06-29 Ibm Anzeigesystem.
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
AU4080597A (en) * 1996-08-23 1998-03-06 Board Of Regents For Oklahoma State University, The Heteroarotinoids-anticancer agents with receptor specificity and tgase activity
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Also Published As

Publication number Publication date
WO2000015612A1 (en) 2000-03-23
BR9913222A (pt) 2001-10-16
SK2612001A3 (en) 2001-11-06
MXPA01001995A (es) 2004-07-30
AU754557B2 (en) 2002-11-21
DE69934238T2 (de) 2007-06-21
PL346248A1 (en) 2002-01-28
TR200100588T2 (tr) 2001-08-21
HUP0104766A3 (en) 2002-08-28
IL141596A (en) 2006-07-05
EP1114028B1 (en) 2006-11-29
AU5634399A (en) 2000-04-03
ES2276530T3 (es) 2007-06-16
HUP0104766A2 (hu) 2002-04-29
EP1114028A1 (en) 2001-07-11
DE69934238D1 (de) 2007-01-11
KR20010085630A (ko) 2001-09-07
PT1114028E (pt) 2007-02-28
CN1323295A (zh) 2001-11-21
US6608084B1 (en) 2003-08-19
NZ509781A (en) 2003-05-30
ATE346841T1 (de) 2006-12-15
NO20010942D0 (no) 2001-02-23
NO20010942L (no) 2001-04-19
CA2341677A1 (en) 2000-03-23
IL141596A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
DK1114028T3 (da) Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion
ATE202567T1 (de) Phosphorsäurediester-derivate
ATE230429T1 (de) Cyanoakrylat klebezusammensetzungen zur glasleimung
SU496737A3 (ru) Способ получени серусодержащих кремнийорганических соединений
ATE108470T1 (de) Polymerisationsverfahren unter verwendung von verbindungen mit polymerisierbaren acylurethan- strukturen.
DE3275192D1 (en) Silicic acid heteropolycondensates and their use in optical lenses, especially contact lenses
FR2699918B1 (fr) Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
FI102374B1 (fi) 1-aryyli-imidatsolipestisidejä
AP2000001924A0 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines.
FI971227A0 (fi) Pyramidinyylipyratsolijohdannaisia
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
TR200201678T2 (tr) Sitalopram hazırlanması için yöntem
DE60303821D1 (de) Organophosphor-verbindungen mit polysulfid-brücke
ATE27257T1 (de) Verfahren zur disproportionierung von silanen.
TR200002950T2 (tr) Matris-Metaloproteinaz önleyicilerinin üretiminde faydalı alkilleştirici engellenmiş sülfonamitlerin işlemi.
ATE447728T1 (de) Lichtempfindliche verbindung und lichtempfindliches harz
CA1205809A (en) Process for the preparation of 2-(thien-2-yl)- and 2- (thien-3-yl)-ethylamine derivatives
EA200001077A3 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции
DE69910140D1 (de) Verfahren zur Sulfurierung von Phosphor-enthaltenden Verbindungen
ES480969A1 (es) Procedimiento para la aclaracion optica de materiales organicos, en especial de tipo textil.
DK2887A (da) Phosphonyl-hydroxyacyl-proliner
TW363967B (en) Bisquaternary ammonium compound of 2,2'- dimethyl-l, l'-binaphthyl and process for their preparation
EA200000876A1 (ru) Дигидробензо(1,4)оксазины и тетрагидрохиноксалины
KR102097352B1 (ko) 실릴기로 보호된 질소 함유 환상 화합물 및 그의 제조 방법
KR960013204A (ko) 4-아릴-2-퍼플루오로알킬-3-옥사졸린-5-온의 제조 방법